1
|
Laureano AF, Vigato AA, Puzer L, de Araujo DR. Recombinant scFv-Fc Anti-kallikrein 7 Antibody-Loaded Thermosensitive Hydrogels Against Skin Desquamation Disorders. ACS APPLIED BIO MATERIALS 2024; 7:4486-4496. [PMID: 38886921 PMCID: PMC11253099 DOI: 10.1021/acsabm.4c00371] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2024] [Revised: 06/01/2024] [Accepted: 06/04/2024] [Indexed: 06/20/2024]
Abstract
Human tissue kallikrein-related peptidase 7 (KLK7) is a serine protease implicated in the physiology of skin desquamation, and its uncontrolled activity can lead to chronic diseases such as psoriasis, atopic dermatitis, and Netherton syndrome. For this reason, kallikrein 7 has been identified as a potential therapeutic target. This work aimed to evaluate Pluronic (PL) hydrogels as topical carriers of four specific scFv-Fc antibodies to inhibit KLK7. The hydrogels comprised PL F127 (30% w/v) alone and a binary F127/P123 (28-2% w/v) system. Each formulation was loaded with 1 μg/mL of each antibody and characterized by physicochemical and pharmaceutical techniques, considering antibody-micelle interactions and hydrogel behavior as smart delivery systems. Results showed that the antibodies were successfully loaded into the PL-based systems, and the sol-gel transition temperature was shifted to high values after the P123 addition. The antibodies released from the gels preserved their rheological properties (G' > G'', 35- to 41-fold) and inhibitory activity against KLK7, even after 24 h. This work presented potential agents targeting KLK7 that may provide strategies for treating skin abnormalities.
Collapse
Affiliation(s)
- Ana Flávia
Santarine Laureano
- Department
of Surgery, Center for Transplantation Sciences, Massachusetts General Hospital & Harvard Medical School, CNY149 13th Street, Charlestown, Boston, Massachusetts 02129, United States
- Centro
de Ciências Naturais e Humanas, Universidade
Federal do ABC, Al. da Universidade, s/n-Anchieta, São
Bernardo do Campo, SP 09606-045, Brazil
| | - Aryane Alves Vigato
- Department
of Biomedical Science (BMV), Faculty of Health and Society, Malmö University, Malmö 20506, Sweden
- Biofilms−Research
Center for Biointerfaces, Malmö University, Malmö 20506, Sweden
| | - Luciano Puzer
- Centro
de Ciências Naturais e Humanas, Universidade
Federal do ABC, Al. da Universidade, s/n-Anchieta, São
Bernardo do Campo, SP 09606-045, Brazil
| | - Daniele Ribeiro de Araujo
- Centro
de Ciências Naturais e Humanas, Universidade
Federal do ABC, Av. dos
Estados, 5001, Bloco A, Torre 3, Santo André, SP 09210-580, Brazil
- Departamento
de Biofísica, Escola Paulista de Medicina, Universidade Federal de São Paulo, Rua Botucatu, 862, Vila Clementino, Sao Paulo, SP 04023-062, Brazil
| |
Collapse
|
2
|
Xiang F, Wang Y, Cao C, Li Q, Deng H, Zheng J, Liu X, Tan X. The Role of Kallikrein 7 in Tumorigenesis. Curr Med Chem 2021; 29:2617-2631. [PMID: 34525904 DOI: 10.2174/0929867328666210915104537] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2021] [Revised: 07/21/2021] [Accepted: 08/02/2021] [Indexed: 11/22/2022]
Abstract
Kallikrein 7 (KLK7) is a secreted serine protease with chymotrypsic protease activity. Abnormally high expression of KLK7 is closely related to the occurrence and development of various types of cancer. Therefore, KLK7 has been identified as a potential target for cancer drug development design in recent years. KLK7 mediates various biological and pathological processes in tumorigenesis, including cell proliferation, migration, invasion, angiogenesis, and cell metabolism, by hydrolyzing a series of substrates such as membrane proteins, extracellular matrix proteins, and cytokines. This review mainly introduces the downstream cell signaling pathways involved in the activation of KLK7 and its substrate-related proteins. This review will not only help us to better understand the mechanisms of KLK7 in regulating biological and pathological processes of cancer cells, but also lay a solid foundation for the design of inhibitors targeting KLK7.
Collapse
Affiliation(s)
- Fengyi Xiang
- Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Medical College, China Three Gorges University, Yichang, 443003. China
| | - Yueqing Wang
- Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Medical College, China Three Gorges University, Yichang, 443003. China
| | - Chunyu Cao
- Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Medical College, China Three Gorges University, Yichang, 443003. China
| | - Qingyun Li
- Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Medical College, China Three Gorges University, Yichang, 443003. China
| | - Hao Deng
- Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Medical College, China Three Gorges University, Yichang, 443003. China
| | - Jun Zheng
- Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Medical College, China Three Gorges University, Yichang, 443003. China.,The First College of Clinical Medical Science, China Three Gorges University, Yichang, 443003, P.R. China
| | - Xiaowen Liu
- Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Medical College, China Three Gorges University, Yichang, 443003. China
| | - Xiao Tan
- Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Medical College, China Three Gorges University, Yichang, 443003. China
| |
Collapse
|
3
|
Zullo V, Górecki M, Guazzelli L, Mezzetta A, Pescitelli G, Iuliano A. Exploiting isohexide scaffolds for the preparation of chiral ionic liquids tweezers. J Mol Liq 2021. [DOI: 10.1016/j.molliq.2020.114528] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
|
4
|
Petrova E, Hovnanian A. Advances in understanding of Netherton syndrome and therapeutic implications. Expert Opin Orphan Drugs 2020. [DOI: 10.1080/21678707.2020.1857724] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- Evgeniya Petrova
- Laboratory of genetic skin diseases, Université de Paris, Imagine Institute, INSERM UMR1163, Paris, France
| | - Alain Hovnanian
- Laboratory of genetic skin diseases, Université de Paris, Imagine Institute, INSERM UMR1163, Paris, France
- Departement of Genetics, AP-HP, Hôpital Necker-Enfants Malades, Paris, France
| |
Collapse
|
5
|
Laureano AFS, Zani MB, Sant'Ana AM, Tognato RC, Lombello CB, do Nascimento MHM, Helmsing S, Fühner V, Hust M, Puzer L. Generation of recombinant antibodies against human tissue kallikrein 7 to treat skin diseases. Bioorg Med Chem Lett 2020; 30:127626. [PMID: 33096161 DOI: 10.1016/j.bmcl.2020.127626] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2020] [Revised: 10/09/2020] [Accepted: 10/14/2020] [Indexed: 12/25/2022]
Abstract
Human tissue kallikreins (KLKs) constitute a family of 15 serine proteases that are distributed in various tissues and implicated in several pathological disorders. KLK7 is an unusual serine protease that presents both trypsin-like and chymotrypsin-like specificity and appears to be upregulated in pathologies that are related to skin desquamation processes, such as atopic dermatitis, psoriasis and Netherton syndrome. In recent years, various groups have worked to develop specific inhibitors for this enzyme, as KLK7 represents a potential target for new therapeutic procedures for diseases related to skin desquamation processes. In this work, we selected nine different single-chain variable fragment antibodies (scFv) from a human naïve phage display library and characterized their inhibitory activities against KLK7. The scFv with the lowest IC50 against KLK7 was affinity maturated, which resulted in the generation of four new scFv-specific antibodies for the target protease. These new antibodies were expressed in the scFv-Fc format in HEK293-6E cells, and the characterization of their inhibitory activities against KLK7 showed that three of them presented IC50 values lower than that of the original antibody. The cytotoxicity analysis of these recombinant antibodies demonstrated that they can be safely used in a cellular model. In conclusion, our research showed that in our case, a phage-display methodology in combination with enzymology assays can be a very suitable tool for the development of inhibitors for KLKs, suggesting a new strategy to identify therapeutic protease inhibitors for diseases related to uncontrolled kallikrein activity.
Collapse
Affiliation(s)
- Ana Flávia S Laureano
- Universidade Federal do ABC - Centro de Ciências Naturais e Humanas, São Bernardo do Campo, São Paulo, Brazil
| | - Marcelo B Zani
- Universidade Federal do ABC - Centro de Ciências Naturais e Humanas, São Bernardo do Campo, São Paulo, Brazil
| | - Aquiles M Sant'Ana
- Universidade Federal do ABC - Centro de Ciências Naturais e Humanas, São Bernardo do Campo, São Paulo, Brazil
| | - Rafael C Tognato
- Universidade Federal do ABC - Centro de Ciências Naturais e Humanas, São Bernardo do Campo, São Paulo, Brazil
| | - Christiane B Lombello
- Universidade Federal do ABC - Centro de Engenharia, Modelagem e Ciências Sociais aplicadas, São Bernardo do Campo, São Paulo, Brazil
| | - Mônica Helena M do Nascimento
- Universidade Federal do ABC - Centro de Engenharia, Modelagem e Ciências Sociais aplicadas, São Bernardo do Campo, São Paulo, Brazil
| | - Saskia Helmsing
- Technische Universität Braunschweig - Abteilung Biotechnologie, Institut für Biochemie, Biotechnologie und Bioinformatik, Braunschweig, Germany
| | - Viola Fühner
- Technische Universität Braunschweig - Abteilung Biotechnologie, Institut für Biochemie, Biotechnologie und Bioinformatik, Braunschweig, Germany
| | - Michael Hust
- Technische Universität Braunschweig - Abteilung Biotechnologie, Institut für Biochemie, Biotechnologie und Bioinformatik, Braunschweig, Germany
| | - Luciano Puzer
- Universidade Federal do ABC - Centro de Ciências Naturais e Humanas, São Bernardo do Campo, São Paulo, Brazil.
| |
Collapse
|
6
|
Di Paolo CT, Diamandis EP, Prassas I. The role of kallikreins in inflammatory skin disorders and their potential as therapeutic targets. Crit Rev Clin Lab Sci 2020; 58:1-16. [PMID: 32568598 DOI: 10.1080/10408363.2020.1775171] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
The skin is a vital organ of the human body, serving numerous protective and functional roles that are essential for survival. Residing in the epidermis are various epidermal proteases responsible for the establishment and regulation of barrier function. The human tissue kallikrein-related peptidase family conserves homeostasis of the skin barrier through their roles in desquamation, antimicrobial defense, innate immune response, and barrier maintenance. The activity of kallikreins is tightly regulated and dysregulation of kallikrein activity is seen to contribute to the formation of several inflammatory skin disorders. This review highlights the roles of kallikreins in skin homeostasis and pathologies. Due to their part in these skin disorders, inhibitors of the skin kallikreins have become attractive therapeutics. Over the past few years, both natural and synthetic inhibitors of several kallikreins have been identified and are undergoing further development as treatments to restore compromised barrier function. This review summarizes the kallikrein inhibitors under development for this purpose. These inhibitors remain promising therapeutics in cases of severe skin inflammation not well managed by current therapies.
Collapse
Affiliation(s)
- Caitlin T Di Paolo
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.,Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada
| | - Eleftherios P Diamandis
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.,Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada.,Department of Clinical Biochemistry, University Health Network, Toronto, Canada
| | - Ioannis Prassas
- Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada
| |
Collapse
|
7
|
de Souza AS, Pacheco BDC, Pinheiro S, Muri EMF, Dias LRS, Lima CHS, Garrett R, de Moraes MBM, de Souza BEG, Puzer L. 3-Acyltetramic acids as a novel class of inhibitors for human kallikreins 5 and 7. Bioorg Med Chem Lett 2019; 29:1094-1098. [PMID: 30833107 DOI: 10.1016/j.bmcl.2019.02.031] [Citation(s) in RCA: 43] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2018] [Revised: 02/25/2019] [Accepted: 02/26/2019] [Indexed: 12/30/2022]
Abstract
Human kallikreins 5 and 7 (KLK5 and KLK7) exhibit trypsin- and chymotrypsin-like activities and are involved in pathologies related to skin desquamation process. A series of new 3-acyltetramic acids were developed as a novel class of inhibitors of KLK5, KLK7 and trypsin enzymes. The nature and length of the acyl chain is crucial to the KLK5, KLK7 and trypsin inhibition activities, and the most potent compounds (but not the most selective) 2b, 2c and 2g showed low micromolar IC50 values. While very few of the compounds were selective for KLK5, the selective inhibition of trypsin against chymotrypsin was achieved. Our molecular modelling studies revealed that the double bond in 2g provided the best fit in the binding site of KLK5, while the hydrogen bonding interactions modulated the best fit of 2c in the binding site of KLK7 due to the hydrophobicity of the cavity.
Collapse
Affiliation(s)
- Acácio S de Souza
- Instituto de Química, Universidade Federal Fluminense, Outeiro de S. João Batista s/n, Centro, 24020-141 Niterói, RJ, Brazil
| | - Barbara D C Pacheco
- Instituto de Química, Universidade Federal Fluminense, Outeiro de S. João Batista s/n, Centro, 24020-141 Niterói, RJ, Brazil
| | - Sergio Pinheiro
- Instituto de Química, Universidade Federal Fluminense, Outeiro de S. João Batista s/n, Centro, 24020-141 Niterói, RJ, Brazil.
| | - Estela M F Muri
- Departamento de Tecnologia Farmacêutica, Faculdade de Farmácia, Universidade Federal Fluminense, Niterói, RJ, Brazil.
| | - Luiza R S Dias
- Departamento de Tecnologia Farmacêutica, Faculdade de Farmácia, Universidade Federal Fluminense, Niterói, RJ, Brazil
| | - Camilo H S Lima
- Departamento de Tecnologia Farmacêutica, Faculdade de Farmácia, Universidade Federal Fluminense, Niterói, RJ, Brazil
| | - Rafael Garrett
- Instituto de Química, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
| | - Mariana B M de Moraes
- Instituto de Química, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
| | - Bruno E G de Souza
- Centro de Ciências Naturais e Humanas, Universidade Federal do ABC, Santo André, SP, Brazil
| | - Luciano Puzer
- Centro de Ciências Naturais e Humanas, Universidade Federal do ABC, Santo André, SP, Brazil
| |
Collapse
|
8
|
Kahler U, Fuchs JE, Goettig P, Liedl KR. An unexpected switch in peptide binding mode: from simulation to substrate specificity. J Biomol Struct Dyn 2018; 36:4072-4084. [PMID: 29210603 PMCID: PMC6334781 DOI: 10.1080/07391102.2017.1407674] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2017] [Accepted: 11/15/2017] [Indexed: 12/12/2022]
Abstract
A ten microsecond molecular dynamics simulation of a kallikrein-related peptidase 7 peptide complex revealed an unexpected change in binding mode. After more than two microseconds unrestrained sampling we observe a spontaneous transition of the binding pose including a 180° rotation around the P1 residue. Subsequently, the substrate peptide occupies the prime side region rather than the cognate non-prime side in a stable conformation. We characterize the unexpected binding mode in terms of contacts, solvent-accessible surface area, molecular interactions and energetic properties. We compare the new pose to inhibitor-bound structures of kallikreins with occupied prime side and find that a similar orientation is adopted. Finally, we apply in silico mutagenesis based on the alternative peptide binding position to explore the prime side specificity of kallikrein-related peptidase 7 and compare it to available experimental data. Our study provides the first microsecond time scale simulation data on a kallikrein protease and shows previously unexplored prime side interactions. Therefore, we expect our study to advance the rational design of inhibitors targeting kallikrein-related peptidase 7, an emerging drug target involved in several skin diseases as well as cancer.
Collapse
Affiliation(s)
- Ursula Kahler
- Faculty of Chemistry and Pharmacy, Institute of General, Inorganic and Theoretical Chemistry, University Innsbruck, Innrain 82, InnsbruckA-6020, Austria
| | - Julian E. Fuchs
- Faculty of Chemistry and Pharmacy, Institute of General, Inorganic and Theoretical Chemistry, University Innsbruck, Innrain 82, InnsbruckA-6020, Austria
| | - Peter Goettig
- Division of Structural Biology, Department of Molecular Biology, University of Salzburg, Billrothstrasse 11, SalzburgA-5020, Austria
| | - Klaus R. Liedl
- Faculty of Chemistry and Pharmacy, Institute of General, Inorganic and Theoretical Chemistry, University Innsbruck, Innrain 82, InnsbruckA-6020, Austria
| |
Collapse
|
9
|
Al-Awadhi FH, Gao B, Rezaei MA, Kwan JC, Li C, Ye T, Paul VJ, Luesch H. Discovery, Synthesis, Pharmacological Profiling, and Biological Characterization of Brintonamides A-E, Novel Dual Protease and GPCR Modulators from a Marine Cyanobacterium. J Med Chem 2018; 61:6364-6378. [PMID: 30015488 PMCID: PMC7341966 DOI: 10.1021/acs.jmedchem.8b00885] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Five novel modified linear peptides named brintonamides A-E (1-5) were discovered from a marine cyanobacterial sample collected from Brinton Channel, Florida Keys. The total synthesis of 1-5 in addition to two other structurally related analogues (6 and 7) was achieved, which provided more material to allow rigorous biological evaluation and SAR studies. Compounds were subjected to cancer-focused phenotypic cell viability and migration assays and orthogonal target-based pharmacological screening platforms to identify their protease and GPCR modulatory activity profiles. The cancer related serine protease kallikrein 7 (KLK7) was inhibited to similar extents with an IC50 near 20 μM by both representative members 1 and 4, which differed in the presence or lack of the N-terminal unit. In contrast to the biochemical protease profiling study, clear SAR was observed in the functional GPCR screens, where five GPCRs in antagonist mode (CCR10, OXTR, SSTR3, TACR2) and agonist mode (CXCR7) were modulated by compounds 1-7 to varying extents. Chemokine receptor type 10 (CCR10) was potently modulated by brintonamide D (4) with an IC50 of 0.44 μM. We performed in silico modeling to understand the structural basis underlying the differences in the antagonistic activity among brintonamides toward CCR10. Because of the significance of KLK7 and CCR10 in cancer progression and metastasis, we demonstrated the ability of brintonamide D (4) at 10 μM to significantly target downstream cellular substrates of KLK7 (Dsg-2 and E-cad) in vitro and to inhibit CCL27-induced CCR10-mediated proliferation and the migration of highly invasive breast cancer cells.
Collapse
Affiliation(s)
- Fatma H. Al-Awadhi
- Department of Medicinal Chemistry, Center for Natural Products, Drug Discovery and Development (CNPD3), University of Florida, 1345 Center Drive, Gainesville, Florida 32610, United States
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kuwait University, P.O. Box 24923, Safat 13110, Kuwait
| | - Bowen Gao
- State Key Laboratory of Chemical Oncogenomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Xili, Nanshan District, Shenzhen, 518055, China
| | - Mohammad A. Rezaei
- Department of Medicinal Chemistry, Center for Natural Products, Drug Discovery and Development (CNPD3), University of Florida, 1345 Center Drive, Gainesville, Florida 32610, United States
- Department of Chemistry, University of Florida, Gainesville, Florida 32611, United States
| | - Jason C. Kwan
- Department of Medicinal Chemistry, Center for Natural Products, Drug Discovery and Development (CNPD3), University of Florida, 1345 Center Drive, Gainesville, Florida 32610, United States
| | - Chenglong Li
- Department of Medicinal Chemistry, Center for Natural Products, Drug Discovery and Development (CNPD3), University of Florida, 1345 Center Drive, Gainesville, Florida 32610, United States
| | - Tao Ye
- State Key Laboratory of Chemical Oncogenomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Xili, Nanshan District, Shenzhen, 518055, China
| | - Valerie J. Paul
- Smithsonian Marine Station, Fort Pierce, 701 Seaway Drive, Fort Pierce, Florida 34949, United States
| | - Hendrik Luesch
- Department of Medicinal Chemistry, Center for Natural Products, Drug Discovery and Development (CNPD3), University of Florida, 1345 Center Drive, Gainesville, Florida 32610, United States
| |
Collapse
|
10
|
Murafuji H, Sakai H, Goto M, Imajo S, Sugawara H, Muto T. Discovery and structure-activity relationship study of 1,3,6-trisubstituted 1,4-diazepane-7-ones as novel human kallikrein 7 inhibitors. Bioorg Med Chem Lett 2017; 27:5272-5276. [PMID: 29102227 DOI: 10.1016/j.bmcl.2017.10.030] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2017] [Revised: 10/13/2017] [Accepted: 10/14/2017] [Indexed: 10/18/2022]
Abstract
Compound 1, composed of a 1,3,6-trisubstituted 1,4-diazepane-7-one, was discovered as a novel human kallikrein 7 (KLK7, stratum corneum chymotryptic enzyme, SCCE) inhibitor, and its derivatives were synthesized and evaluated. Structure-activity relationship studies of the amidoxime unit and benzoic acid part of this new scaffold led to the identification of 25 and 34, which were more potent than the hit compound, 1. The X-ray co-crystal structure of compound 25 and human KLK7 revealed the characteristic interactions and enabled explanations of the structure-activity relationship.
Collapse
Affiliation(s)
- Hidenobu Murafuji
- Asubio Pharma Co., Ltd., 6-4-3 Minatojima-Minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan.
| | - Hiroki Sakai
- Asubio Pharma Co., Ltd., 6-4-3 Minatojima-Minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan
| | - Megumi Goto
- Asubio Pharma Co., Ltd., 6-4-3 Minatojima-Minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan
| | - Seiichi Imajo
- Asubio Pharma Co., Ltd., 6-4-3 Minatojima-Minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan
| | - Hajime Sugawara
- Asubio Pharma Co., Ltd., 6-4-3 Minatojima-Minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan
| | - Tsuyoshi Muto
- Asubio Pharma Co., Ltd., 6-4-3 Minatojima-Minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan.
| |
Collapse
|
11
|
Isosorbide-based peptidomimetics as inhibitors of hepatitis C virus serine protease. Bioorg Med Chem Lett 2017; 27:3661-3665. [DOI: 10.1016/j.bmcl.2017.07.027] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2017] [Revised: 07/04/2017] [Accepted: 07/06/2017] [Indexed: 11/21/2022]
|
12
|
Masurier N, Arama DP, El Amri C, Lisowski V. Inhibitors of kallikrein-related peptidases: An overview. Med Res Rev 2017; 38:655-683. [DOI: 10.1002/med.21451] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2017] [Revised: 04/24/2017] [Accepted: 05/16/2017] [Indexed: 12/11/2022]
Affiliation(s)
- Nicolas Masurier
- Institut des Biomolécules Max Mousseron, UMR 5247, CNRS; Université de Montpellier, ENSCM, UFR des Sciences Pharmaceutiques et Biologiques; Montpellier Cedex France
| | - Dominique P. Arama
- Institut des Biomolécules Max Mousseron, UMR 5247, CNRS; Université de Montpellier, ENSCM, UFR des Sciences Pharmaceutiques et Biologiques; Montpellier Cedex France
| | - Chahrazade El Amri
- Sorbonne Universités, UPMC Univ Paris 06, UMR 8256; Biological Adaptation and Ageing, Integrated Cellular Ageing and Inflammation, Molecular & Functional Enzymology; Paris France
| | - Vincent Lisowski
- Institut des Biomolécules Max Mousseron, UMR 5247, CNRS; Université de Montpellier, ENSCM, UFR des Sciences Pharmaceutiques et Biologiques; Montpellier Cedex France
| |
Collapse
|
13
|
Barros TG, Santos JA, de Souza BE, Sodero ACR, de Souza AM, da Silva DP, Rodrigues CR, Pinheiro S, Dias LR, Abrahim-Vieira B, Puzer L, Muri EM. Discovery of a new isomannide-based peptidomimetic synthetized by Ugi multicomponent reaction as human tissue kallikrein 1 inhibitor. Bioorg Med Chem Lett 2017; 27:314-318. [DOI: 10.1016/j.bmcl.2016.11.051] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2016] [Accepted: 11/17/2016] [Indexed: 01/17/2023]
|
14
|
Synthesis, biological evaluation and molecular modeling of pseudo-peptides based statine as inhibitors for human tissue kallikrein 5. Eur J Med Chem 2016; 112:39-47. [DOI: 10.1016/j.ejmech.2016.01.060] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2015] [Revised: 01/11/2016] [Accepted: 01/30/2016] [Indexed: 02/05/2023]
|
15
|
Avgeris M, Scorilas A. Kallikrein-related peptidases (KLKs) as emerging therapeutic targets: focus on prostate cancer and skin pathologies. Expert Opin Ther Targets 2016; 20:801-18. [PMID: 26941073 DOI: 10.1517/14728222.2016.1147560] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
INTRODUCTION Tissue kallikrein and the kallikrein-related peptidases (KLKs) constitute a family of 15 homologous secreted serine proteases with trypsin- or chymotrypsin-like activities, which participate in a broad spectrum of physiological procedures. Deregulated expression and/or activation of the majority of the family members have been reported in several human diseases, thereby making KLKs ideal targets for therapeutic intervention. AREAS COVERED In the present review, we summarize the role of KLKs in normal human physiology and pathology, focusing on prostate cancer and skin diseases. Furthermore, we discuss the recent advances in the development of KLK-based therapies. A great number of diverse engineered KLKs inhibitors with improved potency, selectivity and immunogenicity have been synthesized by redesigning examples that are endogenous and naturally occurring. Moreover, encouraging results have been documented using KLKs-based vaccines and immunotherapies, as well as KLKs-mediated activation of pro-drugs. Finally, KLKs-targeting aptamers and KLKs-based imaging tools represent novel approaches towards the exploitation of KLKs' therapeutic value. EXPERT OPINION The central/critical roles of KLK family in several human pathologies highlight KLKs as attractive molecular targets for developing novel therapeutics.
Collapse
Affiliation(s)
- Margaritis Avgeris
- a Department of Biochemistry and Molecular Biology, Faculty of Biology , University of Athens , Athens , Greece
| | - Andreas Scorilas
- a Department of Biochemistry and Molecular Biology, Faculty of Biology , University of Athens , Athens , Greece
| |
Collapse
|
16
|
Santos JA, Kondo MY, Freitas RF, dos Santos MH, Ramalho TC, Assis DM, Juliano L, Juliano MA, Puzer L. The natural flavone fukugetin as a mixed-type inhibitor for human tissue kallikreins. Bioorg Med Chem Lett 2016; 26:1485-9. [DOI: 10.1016/j.bmcl.2016.01.039] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2015] [Revised: 01/12/2016] [Accepted: 01/14/2016] [Indexed: 10/22/2022]
|
17
|
Prassas I, Eissa A, Poda G, Diamandis EP. Unleashing the therapeutic potential of human kallikrein-related serine proteases. Nat Rev Drug Discov 2015; 14:183-202. [DOI: 10.1038/nrd4534] [Citation(s) in RCA: 166] [Impact Index Per Article: 18.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
|
18
|
Arama DP, Soualmia F, Lisowski V, Longevial JF, Bosc E, Maillard LT, Martinez J, Masurier N, El Amri C. Pyrido-imidazodiazepinones as a new class of reversible inhibitors of human kallikrein 7. Eur J Med Chem 2015; 93:202-13. [PMID: 25682203 DOI: 10.1016/j.ejmech.2015.02.008] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2014] [Revised: 02/03/2015] [Accepted: 02/06/2015] [Indexed: 10/24/2022]
Abstract
The human tissue kallikrein-7 (KLK7) is a chymotryptic serine protease member of tissue kallikrein family. KLK7 is involved in skin homeostasis and inflammation. Excess of KLK7 activity is also associated with tumor metastasis processes, especially in ovarian carcinomas, prostatic and pancreatic cancers. Development of Kallikrein 7 inhibitors is thus of great interest in oncology but also for treating skin diseases. Most of the developed synthetic inhibitors present several drawbacks such as poor selectivity and unsuitable physico-chemical properties for in vivo use. Recently, we described a practical sequence for the synthesis of imidazopyridine-fused [1,3]-diazepines. Here, we report the identification of pyrido-imidazodiazepinone core as a new potential scaffold to develop selective and competitive inhibitors of kallikrein-related peptidase 7. Structure-activity relationships (SAR), inhibition mechanisms and selectivity as well as cytotoxicity against selected cancer cell lines were investigated.
Collapse
Affiliation(s)
- Dominique P Arama
- Institut des Biomolécules Max Mousseron, UMR 5247, CNRS, Université de Montpellier, UFR des Sciences Pharmaceutiques et Biologiques, 15 Avenue Charles Flahault, 34093 Montpellier Cedex 5, France
| | - Feryel Soualmia
- Sorbonne Universités, UPMC Univ Paris 06, UMR 8256, B2A, Biological Adaptation and Ageing, Integrated Cellular Ageing and Inflammation, Molecular & Functional Enzymology, 7 Quai St Bernard, F-75005 Paris, France
| | - Vincent Lisowski
- Institut des Biomolécules Max Mousseron, UMR 5247, CNRS, Université de Montpellier, UFR des Sciences Pharmaceutiques et Biologiques, 15 Avenue Charles Flahault, 34093 Montpellier Cedex 5, France
| | - Jean-François Longevial
- Institut des Biomolécules Max Mousseron, UMR 5247, CNRS, Université de Montpellier, UFR des Sciences Pharmaceutiques et Biologiques, 15 Avenue Charles Flahault, 34093 Montpellier Cedex 5, France
| | - Elodie Bosc
- Sorbonne Universités, UPMC Univ Paris 06, UMR 8256, B2A, Biological Adaptation and Ageing, Integrated Cellular Ageing and Inflammation, Molecular & Functional Enzymology, 7 Quai St Bernard, F-75005 Paris, France
| | - Ludovic T Maillard
- Institut des Biomolécules Max Mousseron, UMR 5247, CNRS, Université de Montpellier, UFR des Sciences Pharmaceutiques et Biologiques, 15 Avenue Charles Flahault, 34093 Montpellier Cedex 5, France
| | - Jean Martinez
- Institut des Biomolécules Max Mousseron, UMR 5247, CNRS, Université de Montpellier, UFR des Sciences Pharmaceutiques et Biologiques, 15 Avenue Charles Flahault, 34093 Montpellier Cedex 5, France
| | - Nicolas Masurier
- Institut des Biomolécules Max Mousseron, UMR 5247, CNRS, Université de Montpellier, UFR des Sciences Pharmaceutiques et Biologiques, 15 Avenue Charles Flahault, 34093 Montpellier Cedex 5, France.
| | - Chahrazade El Amri
- Sorbonne Universités, UPMC Univ Paris 06, UMR 8256, B2A, Biological Adaptation and Ageing, Integrated Cellular Ageing and Inflammation, Molecular & Functional Enzymology, 7 Quai St Bernard, F-75005 Paris, France.
| |
Collapse
|
19
|
Tan X, Soualmia F, Furio L, Renard JF, Kempen I, Qin L, Pagano M, Pirotte B, El Amri C, Hovnanian A, Reboud-Ravaux M. Toward the first class of suicide inhibitors of kallikreins involved in skin diseases. J Med Chem 2014; 58:598-612. [PMID: 25489658 DOI: 10.1021/jm500988d] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
The inhibition of kallikreins 5 and 7, and possibly kallikrein 14 and matriptase, (that initiates the kallikrein proteolytic cascade) constitutes an innovative way to treat some skin diseases such as Netherton syndrome. We present here the inhibitory properties of coumarin-3-carboxylate derivatives against these enzymes. Our small collection of these versatile organic compounds was enriched by newly synthesized derivatives in order to obtain molecules selective against one, two, three enzymes or acting on the four ones. We evidenced a series of compounds with IC50 values in the nanomolar range. A suicide mechanism was observed against kallikrein 7 whereas the inactivation was either definitive (suicide type) or transient for kallikreins 5 and 14, and matriptase. Most of these potent inhibitors were devoid of cytotoxicity toward healthy human keratinocytes. In situ zymography investigations on skin sections from human kallikrein 5 transgenic mouse revealed significant reduction of the global proteolytic activity by several compounds.
Collapse
Affiliation(s)
- Xiao Tan
- Sorbonne Universités, UPMC University Paris 06, UMR 8256, B2A, Biological Adaptation and Ageing, Integrated Cellular Ageing and Inflammation, Molecular & Functional Enzymology, Institut de Biologie Paris Seine , 7 Quai St Bernard, F-75005 Paris, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Oliveira JPC, Freitas RF, Melo LSD, Barros TG, Santos JAN, Juliano MA, Pinheiro S, Blaber M, Juliano L, Muri EMF, Puzer L. Isomannide-based peptidomimetics as inhibitors for human tissue kallikreins 5 and 7. ACS Med Chem Lett 2014; 5:128-32. [PMID: 24900785 DOI: 10.1021/ml4003698] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2013] [Accepted: 12/06/2013] [Indexed: 02/05/2023] Open
Abstract
Human kallikrein 5 (KLK5) and 7 (KLK7) are potential targets for the treatment of skin inflammation and cancer. Previously, we identified isomannide derivatives as potent and competitive KLK7 inhibitors. The introduction of N-protected amino acids into the isomannide-based scaffold was studied. Some KLK5 inhibitors with submicromolar affinity (K i values of 0.3-0.7 μM) were identified, and they were 6- to 13-fold more potent than our previous hits. Enzyme kinetics studies and the determination of the mechanism of inhibition confirmed that the new isomannide-based derivatives are competitive inhibitors of both KLK5 and KLK7. Molecular docking and MD simulations of selected inhibitors into the KLK5 binding site provide insight into the molecular mechanism by which these compounds interact with the enzyme. The promising results obtained in this study open new prospects on the design and synthesis of highly specific KLK5 and KLK7 inhibitors.
Collapse
Affiliation(s)
- Jocelia P. C. Oliveira
- Centro
de Ciências Naturais e Humanas, Universidade Federal do ABC, Rua Santa
Adélia 166, Bairro Bangu, Santo André
SP, 09210-170, Brazil
| | - Renato F. Freitas
- Department
of Biology, The Johns Hopkins University, Baltimore, Maryland 21218, United States
| | - Leandro Silva de Melo
- Centro
de Ciências Naturais e Humanas, Universidade Federal do ABC, Rua Santa
Adélia 166, Bairro Bangu, Santo André
SP, 09210-170, Brazil
| | - Thalita G. Barros
- Faculdade
de Farmácia, Universidade Federal Fluminense, R. Miguel de Frias, 9 - Icaraı́, Niterói, RJ, 24220-008, Brazil
| | - Jorge A. N. Santos
- Instituto
Federal de Educação, Ciência e Tecnologia do Sul de Minas Gerais, Inconfidentes, MG, 37576-000, Brazil
| | - Maria A. Juliano
- Departamento
de Biofísica, Universidade Federal de São Paulo, Rua Três
de Maio 100, São Paulo, SP, 04107-001, Brasil
| | - Sérgio Pinheiro
- Instituto
de Química, Universidade Federal Fluminense, R. Miguel de Frias, 9 - Icaraı́, Niterói, RJ 24220-008, Brazil
| | - Michael Blaber
- Department
of Biomedical Sciences, Florida State University, 600 West College Avenue, Tallahassee, Florida 32306, United States
| | - Luiz Juliano
- Departamento
de Biofísica, Universidade Federal de São Paulo, Rua Três
de Maio 100, São Paulo, SP, 04107-001, Brasil
| | - Estela M. F. Muri
- Faculdade
de Farmácia, Universidade Federal Fluminense, R. Miguel de Frias, 9 - Icaraı́, Niterói, RJ, 24220-008, Brazil
| | - Luciano Puzer
- Centro
de Ciências Naturais e Humanas, Universidade Federal do ABC, Rua Santa
Adélia 166, Bairro Bangu, Santo André
SP, 09210-170, Brazil
| |
Collapse
|
21
|
Tan X, Bertonati C, Qin L, Furio L, El Amri C, Hovnanian A, Reboud-Ravaux M, Villoutreix BO. Identification by in silico and in vitro screenings of small organic molecules acting as reversible inhibitors of kallikreins. Eur J Med Chem 2013; 70:661-8. [DOI: 10.1016/j.ejmech.2013.10.040] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2013] [Accepted: 10/12/2013] [Indexed: 10/26/2022]
|
22
|
Tan X, Furio L, Reboud-Ravaux M, Villoutreix BO, Hovnanian A, El Amri C. 1,2,4-Triazole derivatives as transient inactivators of kallikreins involved in skin diseases. Bioorg Med Chem Lett 2013; 23:4547-51. [PMID: 23849879 DOI: 10.1016/j.bmcl.2013.06.039] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2013] [Revised: 06/10/2013] [Accepted: 06/12/2013] [Indexed: 11/27/2022]
Abstract
We describe here 1,2,4-triazoles derivatives identified as transient inactivators acting at the nanomolar level on human kallikreins (hK5, hK7 and hK14) and matriptase. Both the nature of the targeted enzymes and structural variations of the inhibitors influence the life-times of acyl-enzymes. These nonpeptidic, transient and low-molecular-weight inhibitors were found to be noncytotoxic against healthy human keratinocytes. These molecules may be useful to counteract dysregulated proteolytic cascades observed in dermatological disorders such as Netherton syndrome.
Collapse
Affiliation(s)
- Xiao Tan
- Enzymologie Moléculaire et Fonctionnelle, UR4, Université Pierre et Marie Curie-Sorbonne Universités (UPMC), Case Courrier 256, 7, Quai St Bernard, 75252 Paris Cedex 05, France
| | | | | | | | | | | |
Collapse
|